Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial

Blood (2014) 124 (26): 3870–3879.

https://doi.org/10.1182/blood-2014-03-563627

Published: 2014

Includes: Supplemental data

Journal Articles

Substantially Improved Outcome of Adult Burkitt Non-Hodgkin Lymphoma and Leukemia Patients with Rituximab and a Short-Intensive Chemotherapy; Report of a Large Prospective Multicenter Trial

Blood (2012) 120 (21): 667.

https://doi.org/10.1182/blood.V120.21.667.667

Published: 2012

Journal Articles

Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies

Nicola Gökbuget, Michael Kneba, Thorsten Raff, Heiko Trautmann, Claus-Rainer Bartram, Renate Arnold, Rainer Fietkau, Mathias Freund, Arnold Ganser, Wolf-Dieter Ludwig, Georg Maschmeyer, Harald Rieder, Stefan Schwartz, Hubert Serve, Eckhard Thiel, Monika Brüggemann, Dieter Hoelzer

Blood (2012) 120 (9): 1868–1876.

https://doi.org/10.1182/blood-2011-09-377713

Published: 2012

Includes: Supplemental data

Journal Articles

Overall Outcome of Relapsed Acute Lymphoblastic Leukemia Can Be Improved by Stem Cell Transplantation and Early Treatment in Stage of Molecular Relapse

Nicola Goekbuget, MD, Daniel Stanze, MD, Renate Arnold, Monika Brueggemann, MD, Rainer Fietkau, MD, Mathias Freund, MD, Arnold Ganser, MD, Wolf-Dieter Ludwig, Georg Maschmeyer, MD, Thorsten Raff, MD, Harald Rieder, MD, Eckhard Thiel, Hubert Serve, MD, Michael Kneba, MD, Dieter Hoelzer, MD

Blood (2011) 118 (21): 250.

https://doi.org/10.1182/blood.V118.21.250.250

Published: 2011

Journal Articles

Whole Genome Amplification with Subsequent High Throughput Sequencing Allows Comprehensive Genome-Wide Analysis of Single Leukemic Cells

Vera Binder, MD, Christoph Bartenhagen, Vera Okpanyi, PhD, Bianca Behrens, Birte Moehlendick, PhD, Hans-Ulrich Klein, PhD, Harald Rieder, MD, Michael Gombert, PhD, Martin Dugas, MD, Nikolas Hendrik Stoecklein, MD, Arndt Borkhardt, MD

Blood (2011) 118 (21): 1437.

https://doi.org/10.1182/blood.V118.21.1437.1437

Published: 2011

Journal Articles

New Definition of Treatment Response in Adult Acute Lymphoblastic Leukemia (ALL): Use of Molecular Markers for Minimal Residual Disease (MRD).

Nicola Goekbuget, MD, Monika Brueggemann, MD, Renate Arnold, MD, Claus-Rainer Bartram, PhD, Rainer Fietkau, MD, Mathias Freund, MD, Arnold Ganser, MD, Michael Kneba, MD, PhD, Thomas Lipp, MD, Wolf-Dieter Ludwig, MD, Georg Maschmeyer, MD, Dorle Messerer, Thorsten Raff, MD, Harald Rieder, MD, Eckhard Thiel, Dieter Hoelzer, MD, PhD

Blood (2009) 114 (22): 90.

https://doi.org/10.1182/blood.V114.22.90.90

Published: 2009

Journal Articles

General Condition and Early Complications Have in Addition to Disease- Specific Factors a Significant Impact on Outcome - Prognostic Factors Revisited in 1657 Adult ALL Patients (15–55 years).

Blood (2008) 112 (11): 1927.

https://doi.org/10.1182/blood.V112.11.1927.1927

Published: 2008

Journal Articles

Improved Outcome in High Risk and Very High Risk ALL by Risk Adapted SCT and in Standard Risk ALL by Intensive Chemotherapy in 713 Adult ALL Patients Treated According to the Prospective GMALL Study 07/2003.

Nicola Gökbuget, MD, Renate Arnold, MD, PhD, Angelika Böhme, MD, PhD, Rainer Fietkau, MD, PhD, Mathias Freund, MD, PhD, Arnold Ganser, MD, PhD, Michael Kneba, MD, PhD, Thomas Lipp, MD, Wolf-Dieter Ludwig, MD, PhD, Georg Maschmeyer, MD, PhD, Dorle Messerer, Harald Rieder, MD, PhD, Eckard Thiel, MD, PhD, Dieter Hoelzer, MD, PhD

Blood (2007) 110 (11): 12.

https://doi.org/10.1182/blood.V110.11.12.12

Published: 2007

Journal Articles

NUP214-ABL1 in adult T-ALL: the GMALL study group experience

Thomas Burmeister, Nicola Gökbuget, Richard Reinhardt, Harald Rieder, Dieter Hoelzer, Stefan Schwartz

Blood (2006) 108 (10): 3556–3559.

https://doi.org/10.1182/blood-2006-04-014514

Published: 2006

Journal Articles

CD10 - pre-B acute lymphoblastic leukemia (ALL) is a distinct high-risk subgroup of adult ALL associated with a high frequency of MLL aberrations: results of the German Multicenter Trials for Adult ALL (GMALL)

Beate Gleissner, Nicola Goekbuget, Harald Rieder, Renate Arnold, Stefan Schwartz, Helmut Diedrich, Claudia Schoch, Barbara Heinze, Christa Fonatsch, Claus R. Bartram, Dieter Hoelzer, Eckhard Thiel, for the GMALL Study Group

Blood (2005) 106 (13): 4054–4056.

https://doi.org/10.1182/blood-2005-05-1866

Published: 2005

Journal Articles

CD10 − Pre-B Acute Lymphoblastic Leukemia (ALL): A Distinct High-Risk Subgroup of Adult ALL.

Beate Gleissner, MD, Nicola Goekbuget, MD, Harald Rieder, MD, Dieter Hoelzer, MD, Eckhard Thiel, MD

Blood (2005) 106 (11): 1443.

https://doi.org/10.1182/blood.V106.11.1443.1443

Published: 2005

Journal Articles

Subtype Adjusted Therapy Improves Outcome of Elderly Patients with Acute Lymphoblastic Leukemia (ALL).

Dieter Hoelzer, MD, PhD, Nicola Goekbuget, MD, Joachim Beck, MD, Thomas Burmeister, MD, Aristoteles Giagounidis, MD, Axel Glasmacher, MD, Heike Pfeifer, MD, Harald Rieder, MD, Mathias Schmid, MD, Eckhard Thiel, MD, PhD, Barbara Wassmann, MD, Oliver Ottmann, MD, PhD

Blood (2004) 104 (11): 2732.

https://doi.org/10.1182/blood.V104.11.2732.2732

Published: 2004

Journal Articles

Early prediction of response in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph + ALL) treated with imatinib

Barbara Wassmann, Heike Pfeifer, Urban J. Scheuring, Anja Binckebanck, Nicola Gökbuget, Johannes Atta, Patrick Brück, Harald Rieder, Claudia Schoch, Lothar Leimer, Rainer Schwerdtfeger, Gerhard Ehninger, Thomas Lipp, Jolanta Perz, Matthias Stelljes, Harald Gschaidmeier, Dieter Hoelzer, Oliver G. Ottmann

Blood (2004) 103 (4): 1495–1498.

https://doi.org/10.1182/blood-2003-01-0154

Published: 2004

Journal Articles

Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis

Beate Gleißner, Nicola Gökbuget, Claus R. Bartram, Bart Janssen, Harald Rieder, Johannes W. G. Janssen, Christa Fonatsch, Axel Heyll, Dimitris Voliotis, Joachim Beck, Thomas Lipp, Gerd Munzert, Jürgen Maurer, Dieter Hoelzer, Eckhard Thiel, the German Multicenter Trials of Adult Acute Lymphoblastic Leukemia Study Group

Blood (2002) 99 (5): 1536–1543.

https://doi.org/10.1182/blood.V99.5.1536

Published: 2002

Journal Articles

Immunophenotypic and Genotypic Features, Clinical Characteristics, and Treatment Outcome of Adult Pro-B Acute Lymphoblastic Leukemia: Results of the German Multicenter Trials GMALL 03/87 and 04/89

Blood (1998) 92 (6): 1898–1909.

https://doi.org/10.1182/blood.V92.6.1898

Published: 1998

NARROW

Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial

Substantially Improved Outcome of Adult Burkitt Non-Hodgkin Lymphoma and Leukemia Patients with Rituximab and a Short-Intensive Chemotherapy; Report of a Large Prospective Multicenter Trial

Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies

Overall Outcome of Relapsed Acute Lymphoblastic Leukemia Can Be Improved by Stem Cell Transplantation and Early Treatment in Stage of Molecular Relapse

Whole Genome Amplification with Subsequent High Throughput Sequencing Allows Comprehensive Genome-Wide Analysis of Single Leukemic Cells

New Definition of Treatment Response in Adult Acute Lymphoblastic Leukemia (ALL): Use of Molecular Markers for Minimal Residual Disease (MRD).

General Condition and Early Complications Have in Addition to Disease- Specific Factors a Significant Impact on Outcome - Prognostic Factors Revisited in 1657 Adult ALL Patients (15–55 years).

Improved Outcome in High Risk and Very High Risk ALL by Risk Adapted SCT and in Standard Risk ALL by Intensive Chemotherapy in 713 Adult ALL Patients Treated According to the Prospective GMALL Study 07/2003.

NUP214-ABL1 in adult T-ALL: the GMALL study group experience

CD10 - pre-B acute lymphoblastic leukemia (ALL) is a distinct high-risk subgroup of adult ALL associated with a high frequency of MLL aberrations: results of the German Multicenter Trials for Adult ALL (GMALL)

CD10 − Pre-B Acute Lymphoblastic Leukemia (ALL): A Distinct High-Risk Subgroup of Adult ALL.

Subtype Adjusted Therapy Improves Outcome of Elderly Patients with Acute Lymphoblastic Leukemia (ALL).

Early prediction of response in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph + ALL) treated with imatinib

Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis

Immunophenotypic and Genotypic Features, Clinical Characteristics, and Treatment Outcome of Adult Pro-B Acute Lymphoblastic Leukemia: Results of the German Multicenter Trials GMALL 03/87 and 04/89

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only